Cibc World Market Inc. Has $6.40 Million Stock Holdings in Elevance Health, Inc. $ELV

Cibc World Market Inc. grew its position in Elevance Health, Inc. (NYSE:ELV) by 24.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 19,807 shares of the company’s stock after buying an additional 3,879 shares during the period. Cibc World Market Inc.’s holdings in Elevance Health were worth $6,400,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Axxcess Wealth Management LLC boosted its stake in shares of Elevance Health by 27.0% in the 2nd quarter. Axxcess Wealth Management LLC now owns 1,436 shares of the company’s stock valued at $558,000 after purchasing an additional 305 shares during the last quarter. Mutual Advisors LLC lifted its holdings in Elevance Health by 17.0% in the second quarter. Mutual Advisors LLC now owns 2,370 shares of the company’s stock valued at $922,000 after buying an additional 345 shares during the period. Arista Wealth Management LLC bought a new position in Elevance Health in the second quarter valued at approximately $537,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Elevance Health during the 2nd quarter worth $15,714,000. Finally, International Assets Investment Management LLC bought a new stake in shares of Elevance Health during the 2nd quarter valued at $38,938,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $346.49 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The company has a market cap of $76.47 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 1.93 and a beta of 0.50. The stock has a fifty day simple moving average of $352.22 and a two-hundred day simple moving average of $332.03. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Leerink Partners lifted their price objective on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research note on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Mizuho set a $413.00 price target on Elevance Health in a research note on Friday, January 9th. UBS Group set a $400.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Finally, Zacks Research raised shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 6th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $390.55.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.